Analyzing Inhibikase Therapeutics and AgomAb Therapeutics

Two small-cap manufacturing companies with different approaches to fibrosis treatment

Apr. 17, 2026 at 4:18am

Got story updates? Submit your updates here. ›

A minimalist studio still life featuring a collection of smooth, geometric shapes and raw materials arranged in a clean, elegant composition, symbolizing the complex biological processes and therapeutic approaches involved in treating fibrotic diseases.Innovative biopharmaceutical companies are developing novel therapies to target the root causes of devastating fibrotic diseases.Atlanta Today

Inhibikase Therapeutics (NASDAQ:IKT) and AgomAb Therapeutics (NASDAQ:AGMB) are both small-cap biopharmaceutical companies focused on developing novel therapies for immunology and inflammatory diseases, with a particular focus on chronic fibrotic conditions. The companies have taken different approaches, with Inhibikase developing an oral, gastrointestinal-restricted small molecule inhibitor for Crohn's disease-related fibrosis, and AgomAb advancing an inhaled small molecule inhibitor for idiopathic pulmonary fibrosis.

Why it matters

Fibrosis represents a major unmet medical need across multiple organ systems, and the TGF-beta signaling pathway has emerged as a key target for therapeutic intervention. However, previous attempts to develop systemic TGF-beta inhibitors have been limited by safety concerns. The local delivery approaches of Inhibikase and AgomAb aim to maximize efficacy while minimizing toxicity, potentially offering new treatment options for patients with devastating fibrotic diseases.

The details

Inhibikase's lead candidate, ontunisertib, is a selective and potent oral inhibitor of the ALK5 (TGF-beta receptor 1) that is designed to act locally in the gastrointestinal tract to treat fibrostenosing Crohn's disease. AgomAb's AGMB-447 is an inhaled small molecule ALK5 inhibitor in development for idiopathic pulmonary fibrosis. Both companies are leveraging validated targets and modalities with the goal of improving upon previous therapeutic approaches.

  • In November 2025, Inhibikase announced positive topline results from the Phase 2a STENOVA trial of ontunisertib in fibrostenosing Crohn's disease patients.
  • Inhibikase is preparing to initiate a Phase 2b trial of ontunisertib in fibrostenosing Crohn's disease in the second half of 2026.
  • AgomAb is conducting a Phase 1 trial with AGMB-447 and expects to report data from IPF patients in the second half of 2026.

The players

Inhibikase Therapeutics

A clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders, including gastrointestinal complications.

AgomAb Therapeutics

A clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications.

Got photos? Submit your photos here. ›

What’s next

Inhibikase is preparing to initiate a Phase 2b trial of ontunisertib in fibrostenosing Crohn's disease in the second half of 2026, and AgomAb expects to report data from its Phase 1 trial of AGMB-447 in idiopathic pulmonary fibrosis patients in the second half of 2026.

The takeaway

Inhibikase and AgomAb are both taking innovative approaches to targeting the TGF-beta signaling pathway to address fibrotic diseases, leveraging local delivery methods to potentially improve efficacy and safety compared to previous systemic inhibitors. The upcoming clinical data readouts will be closely watched as these companies aim to develop new treatment options for patients with devastating fibrotic conditions.